SOURCE-LINKED STUDY SUMMARY
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- SURPASS-4 randomized adults with type 2 diabetes and high cardiovascular risk to once-weekly tirzepatide or titrated insulin glargine.
- Who / model studied
- Participants had inadequately controlled type 2 diabetes despite oral glucose-lowering medications and established or high cardiovascular risk.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- At one year, tirzepatide lowered HbA1c more than glargine and caused less hypoglycemia; adjudicated cardiovascular events were not increased.
- Limitations & context
- The trial used an open-label design.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)02188-7